Edoxaban (DU-176b, trade names Savaysa, Lixiana) is an oral anticoagulant drug which acts as a direct factor Xa inhibitor. It was developed by Daiichi Sankyo and ...
Edoxaban is a medicine available in a number of countries worldwide. A list of US medications equivalent to Edoxaban is available on the Drugs.com website.
Edoxaban is the third factor Xa inhibitor approved for the nonvalvular AF indication, following approvals for rivaroxaban (Xarelto, Bayer) and apixaban (Eliquis ...
Before taking edoxaban, tell your doctor and pharmacist if you are allergic to edoxaban, any other medications, or any of the ingredients in edoxaban tablets.
Daiichi Sankyo, Media & Investors, Media Relations, Press Releases,Daiichi Sankyo Medical Representatives Improve Life-saving Knowledge and Skills
Background Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin ...
Edoxaban, made by the pharmaceutical company Daiichi Sankyo, is one of the class of blood-thinning drugs known as novel oral anticoagulants (NOACs).
Official site of LIXIANA® (edoxaban), a once-daily, oral direct factor Xa inhibitor for patients with nonvalvular atrial fibrillation (nonvalvular afib) or venous ...
Easy to read patient leaflet for edoxaban. Includes indications, proper use, special instructions, precautions, and possible side effects.
UPDATED // The panel members did grapple with the data, despite the overwhelmingly positive vote. Specifically, they were concerned about edoxaban's lack of efficacy ...